News and Information

News2018-05-04T03:12:28+00:00

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan’s Best-in-Class Medical Aesthetics Portfolio and Pipeline DUBLIN, IRELAND and NEWPORT BEACH, CA – SEPTEMBER 14, 2018 - Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of [...]

September 14th, 2018|Categories: Press Releases|

Bonti Announces Presentation Featuring EB-001A at Masters of Aesthetics Symposium

Dr. Jean Carruthers to Highlight Key Aesthetic Clinical Study Results for This Novel Neurotoxin with a Unique Clinical Profile Bonti, a privately-held, clinical-stage biotechnology company, today announced a presentation featuring Phase 2a clinical results for its aesthetic product, EB-001A, at the 5th Annual Masters of Aesthetics Symposium on Friday, August 24th in San Diego, CA. Dr. Jean Carruthers, a [...]

August 23rd, 2018|Categories: Press Releases|

Bonti Announces Successful Completion of Phase 2a Scar Reduction Clinical Study

SHINE-1 Results Suggest EB-001A May Improve Appearance of ScarsBonti, a privately-held, clinical-stage biotechnology company, today announced the topline results of its SHINE-1 Phase 2a clinical trial, the first clinical trial in its SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction. SHINE-1 evaluated EB-001A, Bonti’s aesthetic product candidate, for scar reduction following Mohs surgery. This pilot [...]

August 2nd, 2018|Categories: Press Releases|

Bonti Announces Start of LANTERN-2 Phase 2 Clinical Trial Evaluating EB-001T in Treating Focal Muscle Pain

Follows Completion of LANTERN-1 Clinical Trial Bonti, Inc., an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications, today announced it has initiated dosing in its LANTERN-2 clinical trial, a Phase 2 clinical trial under Bonti’s LANTERN (Long-Acting NeuroToxin-E Relief, Non-opioid) clinical program aimed at treating focal muscle [...]

May 9th, 2018|Categories: Press Releases|

Bonti Announces Scientific Presentation at Premier Aesthetic Plastic Surgery Conference

EB-001T and EB-001A To Be Spotlighted at The Aesthetic Meeting 2018 Bonti, Inc., an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications, today announced a Hot Topics presentation for its therapeutic product candidate, EB-001T, and for its aesthetic product candidate, EB-001A, at the American Society for Aesthetic Plastic [...]

April 25th, 2018|Categories: Press Releases|

Bonti Appoints Dr. Jacob Chacko to Board of Directors

Bonti, a privately-held, clinical-stage biotechnology company, today announced the appointment of Dr. Jacob Chacko to its Board of Directors, effective immediately. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. (NASDAQ: RXDX) since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications, Facility Operations, and IT, and has helped lead over $500 [...]

February 12th, 2018|Categories: Press Releases|